Fondaparinux Pharmacokinetics and Clinical Implications

Introduction to Fondaparinux

Fondaparinux is a synthetic pentasaccharide that selectively inhibits activated factor Xa through antithrombin-mediated mechanisms, with a half-life of approximately 17 hours, enabling once-daily subcutaneous administration 1, 2, 3

The half-life of fondaparinux is approximately 17 hours, which is a key pharmacokinetic characteristic 1, 2, 3
The standard dose of fondaparinux is 2.5 mg subcutaneously once daily 1, 2

The last injection of fondaparinux should be given more than 36 hours before surgery 3, 4
Target levels of fondaparinux should be below the detection threshold (<0.1 mg/mL) before neuraxial procedures, which typically requires stopping for more than 48 hours 3, 5
Fondaparinux can be restarted from the 6th postoperative hour after bleeding risk assessment, with the 17-hour half-life considered when evaluating hemorrhage risk 3, 5

Fondaparinux is contraindicated if creatinine clearance is <30 mL/min due to renal excretion 1, 6
Anti-Xa activity monitoring is not necessary, and fondaparinux does not affect standard coagulation parameters like aPTT or ACT 1, 2

When fondaparinux is used alone during PCI, an additional anticoagulant with anti-IIa activity must be administered to prevent catheter thrombosis, with a recommended regimen of 85 IU/kg of unfractionated heparin as a loading dose (reduced to 60 IU/kg if a GP IIb/IIIa inhibitor is used concomitantly) 1, 2
In patients with acute heparin-induced thrombocytopenia requiring urgent surgery, the long half-life of fondaparinux may necessitate switching to shorter-acting agents like argatroban or bivalirudin if the thrombotic risk is considered too high 3, 4